Piramal Pharma's Greenhouse Gas Emissions Reduction Commitment Validated by SBTi

Monday, 16 September 2024, 22:01

Greenhouse gas emissions reduction is at the forefront of Piramal Pharma's corporate social responsibility initiatives. Recently, the Science Based Targets initiative (SBTi) validated the company's near-term greenhouse gas (GHG) emission reduction targets. With these targets, Piramal Pharma aims to achieve significant sustainability and make measurable progress by FY2030.
LivaRava_Medicine_Default.png
Piramal Pharma's Greenhouse Gas Emissions Reduction Commitment Validated by SBTi

Introduction to Piramal Pharma's Sustainability Journey

Piramal Pharma is actively addressing greenhouse gas emissions through its sustainability initiatives. Recently, the Science Based Targets initiative (SBTi) confirmed the company’s ambitious plans to reduce its GHG emissions. This includes a commitment to cut absolute scope 1 and 2 GHG emissions by 42% by FY2030 from a FY2022 baseline.

Details of GHG Emission Reduction Targets

Piramal Pharma’s initiatives extend to scope 3 GHG emissions, aiming for a reduction of 25% across various activities including purchased goods, energy-related operations, and upstream transportation. This strategy underscores the company's dedication to integrate sustainability into its core business practices.

Impact on the Pharmaceutical Industry

With these commitments, Piramal Pharma stands out as the third global pharmaceutical company in India to earn validation from the SBTi. This not only highlights the company’s corporate social responsibility but also sets a precedent for other pharmaceuticals to enhance their environmental practices.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe